There are ongoing developments related to the 340B federal drug pricing program. Efforts to reform the program continue, with a new report and a proposed rule from the Centers for Medicare and Medicaid Services (CMS) being released. Additionally, Medicare has proposed slashing 340B payments and broadening site-neutral policies in its 2027 payment rule, although the specifics and outcomes of these developments are unclear.